Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-06-10T20:35:36.613Z Has data issue: false hasContentIssue false

P03-317 - Agomelatine Facilitates Benzodiazepine Discontinuation in Schizophrenia with Severe Insomnia

Published online by Cambridge University Press:  17 April 2020

A.L. Morera-Fumero
Affiliation:
Internal Medicine, Dermatology and Psychiatry, University of La Laguna, Spain
E. Diaz-Mesa
Affiliation:
Psychiatry, University Hospital of the Canaries, Spain
P. Abreu-Gonzalez
Affiliation:
Psysiology, University of La Laguna, Santa Cruz de Tenerife, Spain
M. Henry
Affiliation:
Psychiaty, University Hospital of the Canaries, Tenerife, Spain
S. Yelmo
Affiliation:
Psychiatry, University Hospital of the Canaries, Spain
L. Fernandez-Lopez
Affiliation:
Psychiatry, University Hospital of the Canaries, Spain
R. Gracia-Marco
Affiliation:
Psychiatry, University of La Laguna, Santa Cruz de Tenerife, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We present the case of a schizophrenic patient with severe insomnia that had a partial response to high doses of benzodiazepines and sedating antipsychotics. Treatment with agomelatine allowed to suspend benzodiazepine treatment and restore quality of sleep.

Case report

Mr. Y is a 36 year old male patient diagnosed with simple schizophrenia that has complained of insomnia since the age of sixteen. During the last three years the treatment that the patient was following was stable and consisted of 100 mg of diazepam, 300 mg of levomepromazine and 120 mg of clotiapine every night. During the last year 60 mg of duloxetine were added to treat a moderate depression. His mood improved with the prescribed treatment, but eleven months later it worsened. In an attempt to simultaneously treat the mood and the sleep disorder, during a period of 4 days, a dosis of 12.5 mg of aglomelatin at dinner was introduced while the morning dose of duloxetine was reduced to 30mg. On the fifth day, agomelatine was increased to 25 mg at dinner while duloxetine was suspended. The antipsychotic treatment was kept stable while the patient was instructed to reduce 10 mg of diazepam every week until next appointment one month later. In the next appointment the patient had completely suspended diazepam one week before the appointment. The patient referred improved sleep quality and no rebound insomnia.

Conclusion

Agomelatine may be a valid treatment of insomnia in schizophrenia.

Type
Psychopharmacological treatment and biological therapies
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.